Company profile: Corline Biomedical
1.1 - Company Overview
Company description
- Provider of heparin-based solutions to improve kidney transplantation, cell therapies and regenerative medicine. Offers Renaparin to enhance kidney transplant outcomes and Cytoparin for cell therapies and treatment of type 1 diabetes, using proprietary heparin technology.
Products and services
- Cytoparin: Proprietary heparin technology product architected for cell therapies and Type 1 diabetes treatment, supporting targeted cellular applications in therapeutic contexts
- Heparin-Based Regenerative Medicine Products: Engineers and produces heparin-based products for applications in the evolving field of regenerative medicine, extending the company’s heparin technology into broader regenerative use cases
- Renaparin: Proprietary heparin technology product developed to improve kidney transplantation outcomes, concentrated on outcome enhancement across kidney transplant applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Corline Biomedical
Metabolon
HQ: United States
Website
- Description: Provider of metabolomics solutions for life sciences research, diagnostics, and precision medicine, offering a Global Discovery Panel for broad metabolite identification and quantification, Targeted Panels and Assays covering 1,000+ metabolites and lipids, Complex Lipids and Bile Acids panels, untargeted metabolomics for biomarker discovery, and metabogenomics integrating metabolomics and genomics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Metabolon company profile →
CymaBay
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical development and commercialization of proprietary new medicines for important human diseases, including Seladelpar—an investigational treatment for primary biliary cholangitis—and PBC-focused clinical trials such as IDEAL, AFFIRM, PBC with Hepatic Impairment, ASSURE, and RESPONSE.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CymaBay company profile →
GRI Bio
HQ: United States
Website
- Description: Provider of therapies for inflammatory and autoimmune diseases, including GRI-0621, an oral inhibitor of iNKT cell activity for idiopathic pulmonary fibrosis, and GRI-0803, a novel activator of human type 2 NKT cells for autoimmune disorders with an initial focus on systemic lupus erythematosus, supported by a proprietary library of over 500 compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GRI Bio company profile →
Millendo Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development, previously primarily focused on developing novel treatments for endocrine diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Millendo Therapeutics company profile →
Akarna Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development of novel small molecule therapeutics targeting inflammatory and fibrotic diseases, including a non-bile acid FXR agonist for nonalcoholic steatohepatitis (NASH), aiming to deliver best-in-class treatments for chronic liver diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akarna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Corline Biomedical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Corline Biomedical
2.2 - Growth funds investing in similar companies to Corline Biomedical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Corline Biomedical
4.2 - Public trading comparable groups for Corline Biomedical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →